ADRs came under pressure in the premarket on Thursday after the company announced its decision to halt a clinical program ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...

An independent data monitoring board found that BeiGene’s ociperlimab was unlikely to significantly boost overall survival in ...

Ociperlimab is described as a humanised IgG1 monoclonal antibody with the potential to enhance T cell-mediated immune ...

BeiGene is ending development of its experimental lung-cancer treatment ociperlimab following the failure of a late-stage study. BeiGene on Thursday said it is stopping a Phase 3 trial of ociperlimab ...

TIGIT, in particular, has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody vibostolimab ...

BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT ...

BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later.

BeiGene (ONC) announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a ...

BeiGene (NasdaqGS:ONC) has climbed 32% over the past quarter, against a backdrop of significant industry challenges and broad market declines. The company's positive momentum can be attributed to the ...

BeiGene (NASDAQ:ONC ... a clinical program targeting its antibody therapy ociperlimab (BGB-A1217) in lung cancer in reaction to disappointing safety and efficacy data. The cancer drug developer ...

BeiGene is ending development of its experimental lung-cancer treatment ociperlimab following the failure of a late-stage study. BeiGene on Thursday said it is stopping a Phase 3 trial of ...